MCP-1 Binding Nucleic Acids for Specific Therapeutic Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a specific and effective means to interact with MCP-1, a chemokine involved in various diseases, necessitating the development of nucleic acids that can specifically bind to MCP-1 for therapeutic and diagnostic applications.
Innovation Solution
The use of nucleic acids with specific sequences, such as those described in SEQ.ID.No. 87 to 115, that can bind to MCP-1, including types 1A, 1B, 2, 3, and 4 nucleic acids, which form double-stranded structures capable of interacting with MCP-1, allowing for the development of medicaments and diagnostic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods are used to interact with MCP-1, then general chemokine research can be conducted, but specific and effective interaction with MCP-1 cannot be achieved
Solution Approach 1:
The patent applies parameter changes by modifying nucleic acid sequences to create specific binding configurations that recognize and bind to MCP-1 with high specificity. The invention identifies and utilizes specific nucleic acid sequence parameters (as shown in SEQ.ID.No. 87 to 115) that enable selective interaction with MCP-1, transforming general nucleic acid molecules into targeted binding agents for therapeutic and diagnostic applications
2Reliability
If nucleic acids with specific sequences are designed to bind MCP-1, then specific interaction and therapeutic efficacy are improved, but complexity of nucleic acid design and characterization increases
Solution Approach 1:
The patent applies segmentation by dividing the nucleic acid binding molecule into distinct functional regions or domains that can be independently characterized and optimized. The nucleic acid sequences are organized into specific structural elements (as evidenced by the classification into types 1A, 1B, 2, 3, and 4) that can be separately designed, synthesized, and tested, simplifying the overall design process while maintaining high binding specificity
Solution Approach 2:
The patent systematically varies nucleic acid sequence parameters to optimize binding specificity. By changing specific nucleotide sequences and structural parameters, the invention creates a library of nucleic acid variants that can be screened for optimal MCP-1 binding, thereby managing design complexity through parameter optimization rather than random design
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These nucleic acids provide a specific interaction with MCP-1, enabling the treatment and diagnosis of diseases characterized by MCP-1 involvement, offering a targeted approach to modulate MCP-1 activity and detect its levels effectively.
Implementation Method 1
nucleic acids with specific sequences, such as those described in SEQ.ID.No. 87 to 115, that can bind to MCP-1, including types 1A, 1B, 2, 3, and 4 nucleic acids, which form double-stranded structures capable of interacting with MCP-1
Data Source
AI summary
The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 87 to 115.